Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) Stock Competitors & Peer Comparison
See (IOVA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IOVA | $3.55 | -13.20% | 1.3B | -3.26 | -$1.09 | N/A |
| VRTX | $425.00 | -0.62% | 107.9B | 25.22 | $16.85 | N/A |
| REGN | $709.10 | -1.66% | 73B | 17.29 | $40.99 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $787.31 | -2.51% | 48.7B | 40.21 | $19.58 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $295.91 | -2.34% | 39.5B | 74.54 | $3.97 | N/A |
| RVMD | $142.51 | -5.67% | 30.3B | -20.02 | -$7.12 | N/A |
| UTHR | $569.18 | -4.62% | 24.9B | 21.03 | $27.06 | N/A |
| BNTX | $93.02 | -2.35% | 23.5B | -15.63 | -$5.95 | N/A |
Stock Comparison
IOVA vs VRTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, VRTX has a market cap of 107.9B. Regarding current trading prices, IOVA is priced at $3.55, while VRTX trades at $425.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas VRTX's P/E ratio is 25.22. In terms of profitability, IOVA's ROE is -0.50%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, IOVA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VRTX's competition here
IOVA vs REGN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, REGN has a market cap of 73B. Regarding current trading prices, IOVA is priced at $3.55, while REGN trades at $709.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas REGN's P/E ratio is 17.29. In terms of profitability, IOVA's ROE is -0.50%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check REGN's competition here
IOVA vs VRNA Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IOVA is priced at $3.55, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IOVA's ROE is -0.50%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, IOVA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VRNA's competition here
IOVA vs ARGX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ARGX has a market cap of 48.7B. Regarding current trading prices, IOVA is priced at $3.55, while ARGX trades at $787.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ARGX's P/E ratio is 40.21. In terms of profitability, IOVA's ROE is -0.50%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, IOVA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ARGX's competition here
IOVA vs SGEN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IOVA is priced at $3.55, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IOVA's ROE is -0.50%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IOVA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SGEN's competition here
IOVA vs ALNY Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, IOVA is priced at $3.55, while ALNY trades at $295.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ALNY's P/E ratio is 74.54. In terms of profitability, IOVA's ROE is -0.50%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, IOVA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ALNY's competition here
IOVA vs RVMD Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RVMD has a market cap of 30.3B. Regarding current trading prices, IOVA is priced at $3.55, while RVMD trades at $142.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RVMD's P/E ratio is -20.02. In terms of profitability, IOVA's ROE is -0.50%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, IOVA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RVMD's competition here
IOVA vs UTHR Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, UTHR has a market cap of 24.9B. Regarding current trading prices, IOVA is priced at $3.55, while UTHR trades at $569.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas UTHR's P/E ratio is 21.03. In terms of profitability, IOVA's ROE is -0.50%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IOVA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check UTHR's competition here
IOVA vs BNTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BNTX has a market cap of 23.5B. Regarding current trading prices, IOVA is priced at $3.55, while BNTX trades at $93.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BNTX's P/E ratio is -15.63. In terms of profitability, IOVA's ROE is -0.50%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, IOVA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BNTX's competition here
IOVA vs INSM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, INSM has a market cap of 22.6B. Regarding current trading prices, IOVA is priced at $3.55, while INSM trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas INSM's P/E ratio is -16.32. In terms of profitability, IOVA's ROE is -0.50%, compared to INSM's ROE of -1.30%. Regarding short-term risk, IOVA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for IOVA.Check INSM's competition here
IOVA vs RPRX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RPRX has a market cap of 21.5B. Regarding current trading prices, IOVA is priced at $3.55, while RPRX trades at $50.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RPRX's P/E ratio is 26.42. In terms of profitability, IOVA's ROE is -0.50%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, IOVA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RPRX's competition here
IOVA vs ROIV Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ROIV has a market cap of 20.2B. Regarding current trading prices, IOVA is priced at $3.55, while ROIV trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ROIV's P/E ratio is -24.17. In terms of profitability, IOVA's ROE is -0.50%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IOVA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ROIV's competition here
IOVA vs BGNE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IOVA is priced at $3.55, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IOVA's ROE is -0.50%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, IOVA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BGNE's competition here
IOVA vs INCY Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, INCY has a market cap of 19.5B. Regarding current trading prices, IOVA is priced at $3.55, while INCY trades at $97.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas INCY's P/E ratio is 13.77. In terms of profitability, IOVA's ROE is -0.50%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IOVA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check INCY's competition here
IOVA vs MRNA Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MRNA has a market cap of 19.3B. Regarding current trading prices, IOVA is priced at $3.55, while MRNA trades at $48.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MRNA's P/E ratio is -6.69. In terms of profitability, IOVA's ROE is -0.50%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, IOVA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MRNA's competition here
IOVA vs DNA-WT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IOVA is priced at $3.55, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IOVA's ROE is -0.50%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, IOVA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check DNA-WT's competition here
IOVA vs GMAB Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, GMAB has a market cap of 16.7B. Regarding current trading prices, IOVA is priced at $3.55, while GMAB trades at $27.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas GMAB's P/E ratio is 17.57. In terms of profitability, IOVA's ROE is -0.50%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check GMAB's competition here
IOVA vs ASND Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, IOVA is priced at $3.55, while ASND trades at $246.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ASND's P/E ratio is -55.81. In terms of profitability, IOVA's ROE is -0.50%, compared to ASND's ROE of +1.28%. Regarding short-term risk, IOVA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ASND's competition here
IOVA vs JAZZ Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, JAZZ has a market cap of 14.2B. Regarding current trading prices, IOVA is priced at $3.55, while JAZZ trades at $226.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas JAZZ's P/E ratio is 2063.27. In terms of profitability, IOVA's ROE is -0.50%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, IOVA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check JAZZ's competition here
IOVA vs SMMT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, SMMT has a market cap of 13.3B. Regarding current trading prices, IOVA is priced at $3.55, while SMMT trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas SMMT's P/E ratio is -10.79. In terms of profitability, IOVA's ROE is -0.50%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, IOVA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SMMT's competition here
IOVA vs BBIO Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, IOVA is priced at $3.55, while BBIO trades at $67.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BBIO's P/E ratio is -17.84. In terms of profitability, IOVA's ROE is -0.50%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, IOVA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BBIO's competition here
IOVA vs KRTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IOVA is priced at $3.55, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IOVA's ROE is -0.50%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IOVA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KRTX's competition here
IOVA vs IONS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, IONS has a market cap of 12.6B. Regarding current trading prices, IOVA is priced at $3.55, while IONS trades at $76.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas IONS's P/E ratio is -37.82. In terms of profitability, IOVA's ROE is -0.50%, compared to IONS's ROE of -0.59%. Regarding short-term risk, IOVA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IONS's competition here
IOVA vs MDGL Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, IOVA is priced at $3.55, while MDGL trades at $534.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MDGL's P/E ratio is -41.59. In terms of profitability, IOVA's ROE is -0.50%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, IOVA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MDGL's competition here
IOVA vs EXEL Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, EXEL has a market cap of 11.7B. Regarding current trading prices, IOVA is priced at $3.55, while EXEL trades at $46.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas EXEL's P/E ratio is 15.30. In terms of profitability, IOVA's ROE is -0.50%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, IOVA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check EXEL's competition here
IOVA vs AXSM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, AXSM has a market cap of 11.3B. Regarding current trading prices, IOVA is priced at $3.55, while AXSM trades at $220.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas AXSM's P/E ratio is -59.01. In terms of profitability, IOVA's ROE is -0.50%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, IOVA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check AXSM's competition here
IOVA vs RNAM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IOVA is priced at $3.55, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IOVA's ROE is -0.50%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IOVA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RNAM's competition here
IOVA vs ARWR Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ARWR has a market cap of 10.9B. Regarding current trading prices, IOVA is priced at $3.55, while ARWR trades at $77.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ARWR's P/E ratio is 48.72. In terms of profitability, IOVA's ROE is -0.50%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, IOVA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ARWR's competition here
IOVA vs BMRN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, IOVA is priced at $3.55, while BMRN trades at $54.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BMRN's P/E ratio is 38.94. In terms of profitability, IOVA's ROE is -0.50%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, IOVA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BMRN's competition here
IOVA vs RXDX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IOVA is priced at $3.55, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IOVA's ROE is -0.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RXDX's competition here
IOVA vs CYTK Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, IOVA is priced at $3.55, while CYTK trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CYTK's P/E ratio is -10.85. In terms of profitability, IOVA's ROE is -0.50%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, IOVA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CYTK's competition here
IOVA vs KRYS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, KRYS has a market cap of 8.7B. Regarding current trading prices, IOVA is priced at $3.55, while KRYS trades at $296.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas KRYS's P/E ratio is 39.67. In terms of profitability, IOVA's ROE is -0.50%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IOVA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KRYS's competition here
IOVA vs IMGN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IOVA is priced at $3.55, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IOVA's ROE is -0.50%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IOVA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IMGN's competition here
IOVA vs BPMC Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IOVA is priced at $3.55, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IOVA's ROE is -0.50%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IOVA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BPMC's competition here
IOVA vs CERE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IOVA is priced at $3.55, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CERE's P/E ratio is -16.47. In terms of profitability, IOVA's ROE is -0.50%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IOVA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CERE's competition here
IOVA vs ABVX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ABVX has a market cap of 8.2B. Regarding current trading prices, IOVA is priced at $3.55, while ABVX trades at $124.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ABVX's P/E ratio is -21.98. In terms of profitability, IOVA's ROE is -0.50%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, IOVA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ABVX's competition here
IOVA vs IBRX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, IBRX has a market cap of 8B. Regarding current trading prices, IOVA is priced at $3.55, while IBRX trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas IBRX's P/E ratio is -19.40. In terms of profitability, IOVA's ROE is -0.50%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, IOVA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IBRX's competition here
IOVA vs TECH Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, IOVA is priced at $3.55, while TECH trades at $50.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas TECH's P/E ratio is 96.06. In terms of profitability, IOVA's ROE is -0.50%, compared to TECH's ROE of +0.05%. Regarding short-term risk, IOVA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TECH's competition here
IOVA vs HALO Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, HALO has a market cap of 7.7B. Regarding current trading prices, IOVA is priced at $3.55, while HALO trades at $65.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas HALO's P/E ratio is 25.46. In terms of profitability, IOVA's ROE is -0.50%, compared to HALO's ROE of +0.93%. Regarding short-term risk, IOVA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check HALO's competition here
IOVA vs NUVL Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, IOVA is priced at $3.55, while NUVL trades at $102.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas NUVL's P/E ratio is -17.50. In terms of profitability, IOVA's ROE is -0.50%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IOVA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check NUVL's competition here
IOVA vs PCVX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, IOVA is priced at $3.55, while PCVX trades at $51.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas PCVX's P/E ratio is -9.14. In terms of profitability, IOVA's ROE is -0.50%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, IOVA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PCVX's competition here
IOVA vs MTSR Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IOVA is priced at $3.55, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IOVA's ROE is -0.50%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IOVA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MTSR's competition here
IOVA vs PRAX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, IOVA is priced at $3.55, while PRAX trades at $333.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas PRAX's P/E ratio is -24.72. In terms of profitability, IOVA's ROE is -0.50%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, IOVA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PRAX's competition here
IOVA vs KYMR Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, IOVA is priced at $3.55, while KYMR trades at $84.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas KYMR's P/E ratio is -23.64. In terms of profitability, IOVA's ROE is -0.50%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, IOVA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KYMR's competition here
IOVA vs TGTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, TGTX has a market cap of 6.9B. Regarding current trading prices, IOVA is priced at $3.55, while TGTX trades at $43.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas TGTX's P/E ratio is 15.53. In terms of profitability, IOVA's ROE is -0.50%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, IOVA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TGTX's competition here
IOVA vs MRUS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IOVA is priced at $3.55, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IOVA's ROE is -0.50%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IOVA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MRUS's competition here
IOVA vs ACLX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IOVA is priced at $3.55, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IOVA's ROE is -0.50%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IOVA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ACLX's competition here
IOVA vs RYTM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $3.55, while RYTM trades at $96.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RYTM's P/E ratio is -30.74. In terms of profitability, IOVA's ROE is -0.50%, compared to RYTM's ROE of -2.04%. Regarding short-term risk, IOVA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RYTM's competition here
IOVA vs RETA Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $3.55, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RETA's P/E ratio is -66.29. In terms of profitability, IOVA's ROE is -0.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IOVA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RETA's competition here
IOVA vs PTGX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, IOVA is priced at $3.55, while PTGX trades at $98.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas PTGX's P/E ratio is -54.61. In terms of profitability, IOVA's ROE is -0.50%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, IOVA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PTGX's competition here
IOVA vs CELC Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CELC has a market cap of 6.3B. Regarding current trading prices, IOVA is priced at $3.55, while CELC trades at $130.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CELC's P/E ratio is -29.84. In terms of profitability, IOVA's ROE is -0.50%, compared to CELC's ROE of -2.03%. Regarding short-term risk, IOVA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CELC's competition here
IOVA vs BLTE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, IOVA is priced at $3.55, while BLTE trades at $156.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BLTE's P/E ratio is -67.83. In terms of profitability, IOVA's ROE is -0.50%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, IOVA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BLTE's competition here
IOVA vs CNTA Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, IOVA is priced at $3.55, while CNTA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CNTA's P/E ratio is -27.13. In terms of profitability, IOVA's ROE is -0.50%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IOVA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CNTA's competition here
IOVA vs ALKS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, IOVA is priced at $3.55, while ALKS trades at $35.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ALKS's P/E ratio is 39.33. In terms of profitability, IOVA's ROE is -0.50%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, IOVA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ALKS's competition here
IOVA vs CGON Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CGON has a market cap of 5.8B. Regarding current trading prices, IOVA is priced at $3.55, while CGON trades at $69.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CGON's P/E ratio is -33.26. In terms of profitability, IOVA's ROE is -0.50%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IOVA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CGON's competition here
IOVA vs COGT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, IOVA is priced at $3.55, while COGT trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas COGT's P/E ratio is -16.03. In terms of profitability, IOVA's ROE is -0.50%, compared to COGT's ROE of -0.83%. Regarding short-term risk, IOVA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check COGT's competition here
IOVA vs CDTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IOVA is priced at $3.55, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IOVA's ROE is -0.50%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IOVA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CDTX's competition here
IOVA vs CAI Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CAI has a market cap of 5.6B. Regarding current trading prices, IOVA is priced at $3.55, while CAI trades at $19.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CAI's P/E ratio is -6.16. In terms of profitability, IOVA's ROE is -0.50%, compared to CAI's ROE of +0.25%. Regarding short-term risk, IOVA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CAI's competition here
IOVA vs IMVT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.55, while IMVT trades at $27.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas IMVT's P/E ratio is -10.19. In terms of profitability, IOVA's ROE is -0.50%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IOVA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check IMVT's competition here
IOVA vs ABCM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.55, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IOVA's ROE is -0.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IOVA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ABCM's competition here
IOVA vs ISEE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.55, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IOVA's ROE is -0.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IOVA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ISEE's competition here
IOVA vs CORT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $3.55, while CORT trades at $51.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CORT's P/E ratio is 145.86. In terms of profitability, IOVA's ROE is -0.50%, compared to CORT's ROE of +0.08%. Regarding short-term risk, IOVA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CORT's competition here
IOVA vs PTCT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $3.55, while PTCT trades at $64.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas PTCT's P/E ratio is 7.51. In terms of profitability, IOVA's ROE is -0.50%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, IOVA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check PTCT's competition here
IOVA vs SRRK Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $3.55, while SRRK trades at $46.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas SRRK's P/E ratio is -14.12. In terms of profitability, IOVA's ROE is -0.50%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, IOVA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SRRK's competition here
IOVA vs LEGN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $3.55, while LEGN trades at $28.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas LEGN's P/E ratio is -17.64. In terms of profitability, IOVA's ROE is -0.50%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, IOVA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check LEGN's competition here
IOVA vs FBIOX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $3.55, while FBIOX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IOVA's ROE is -0.50%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IOVA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check FBIOX's competition here
IOVA vs APLS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $3.55, while APLS trades at $41.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas APLS's P/E ratio is 227.83. In terms of profitability, IOVA's ROE is -0.50%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IOVA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check APLS's competition here
IOVA vs MIRM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, IOVA is priced at $3.55, while MIRM trades at $102.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MIRM's P/E ratio is -219.00. In terms of profitability, IOVA's ROE is -0.50%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, IOVA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MIRM's competition here
IOVA vs APGE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, IOVA is priced at $3.55, while APGE trades at $81.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas APGE's P/E ratio is -19.39. In terms of profitability, IOVA's ROE is -0.50%, compared to APGE's ROE of -0.37%. Regarding short-term risk, IOVA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check APGE's competition here
IOVA vs CRSP Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, IOVA is priced at $3.55, while CRSP trades at $52.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CRSP's P/E ratio is -8.50. In terms of profitability, IOVA's ROE is -0.50%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CRSP's competition here
IOVA vs TERN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IOVA is priced at $3.55, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas TERN's P/E ratio is -51.41. In terms of profitability, IOVA's ROE is -0.50%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IOVA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TERN's competition here
IOVA vs CRNX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CRNX has a market cap of 4.6B. Regarding current trading prices, IOVA is priced at $3.55, while CRNX trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CRNX's P/E ratio is -8.78. In terms of profitability, IOVA's ROE is -0.50%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, IOVA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CRNX's competition here
IOVA vs FOLD Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.55, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IOVA's ROE is -0.50%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IOVA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check FOLD's competition here
IOVA vs AKRO Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.55, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IOVA's ROE is -0.50%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check AKRO's competition here
IOVA vs ALPN Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $3.55, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IOVA's ROE is -0.50%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IOVA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ALPN's competition here
IOVA vs MANE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, IOVA is priced at $3.55, while MANE trades at $107.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MANE's P/E ratio is -45.32. In terms of profitability, IOVA's ROE is -0.50%, compared to MANE's ROE of -0.76%. Regarding short-term risk, IOVA is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MANE's competition here
IOVA vs XENE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, IOVA is priced at $3.55, while XENE trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas XENE's P/E ratio is -12.84. In terms of profitability, IOVA's ROE is -0.50%, compared to XENE's ROE of -0.56%. Regarding short-term risk, IOVA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check XENE's competition here
IOVA vs SYRE Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, IOVA is priced at $3.55, while SYRE trades at $73.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas SYRE's P/E ratio is -34.48. In terms of profitability, IOVA's ROE is -0.50%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SYRE's competition here
IOVA vs OPT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IOVA is priced at $3.55, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas OPT's P/E ratio is -1.52. In terms of profitability, IOVA's ROE is -0.50%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IOVA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check OPT's competition here
IOVA vs KNSA Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, KNSA has a market cap of 4.2B. Regarding current trading prices, IOVA is priced at $3.55, while KNSA trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas KNSA's P/E ratio is 59.93. In terms of profitability, IOVA's ROE is -0.50%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, IOVA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check KNSA's competition here
IOVA vs LGND Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, LGND has a market cap of 4.2B. Regarding current trading prices, IOVA is priced at $3.55, while LGND trades at $210.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas LGND's P/E ratio is 34.31. In terms of profitability, IOVA's ROE is -0.50%, compared to LGND's ROE of +0.16%. Regarding short-term risk, IOVA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check LGND's competition here
IOVA vs MRTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IOVA is priced at $3.55, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IOVA's ROE is -0.50%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IOVA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check MRTX's competition here
IOVA vs NAMS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, IOVA is priced at $3.55, while NAMS trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas NAMS's P/E ratio is -20.26. In terms of profitability, IOVA's ROE is -0.50%, compared to NAMS's ROE of -0.23%. Regarding short-term risk, IOVA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check NAMS's competition here
IOVA vs TVTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, IOVA is priced at $3.55, while TVTX trades at $42.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas TVTX's P/E ratio is -85.32. In terms of profitability, IOVA's ROE is -0.50%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, IOVA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TVTX's competition here
IOVA vs ACAD Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, IOVA is priced at $3.55, while ACAD trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ACAD's P/E ratio is 9.81. In terms of profitability, IOVA's ROE is -0.50%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, IOVA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ACAD's competition here
IOVA vs EWTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, EWTX has a market cap of 3.8B. Regarding current trading prices, IOVA is priced at $3.55, while EWTX trades at $35.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas EWTX's P/E ratio is -21.83. In terms of profitability, IOVA's ROE is -0.50%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, IOVA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check EWTX's competition here
IOVA vs CPRX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, IOVA is priced at $3.55, while CPRX trades at $31.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CPRX's P/E ratio is 18.55. In terms of profitability, IOVA's ROE is -0.50%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IOVA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CPRX's competition here
IOVA vs RYZB Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IOVA is priced at $3.55, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IOVA's ROE is -0.50%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IOVA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check RYZB's competition here
IOVA vs CBAY Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IOVA is priced at $3.55, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IOVA's ROE is -0.50%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IOVA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check CBAY's competition here
IOVA vs LQDA Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, IOVA is priced at $3.55, while LQDA trades at $42.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas LQDA's P/E ratio is -52.85. In terms of profitability, IOVA's ROE is -0.50%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, IOVA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check LQDA's competition here
IOVA vs VKTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, IOVA is priced at $3.55, while VKTX trades at $31.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas VKTX's P/E ratio is -7.61. In terms of profitability, IOVA's ROE is -0.50%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, IOVA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VKTX's competition here
IOVA vs TLX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, IOVA is priced at $3.55, while TLX trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas TLX's P/E ratio is -533.00. In terms of profitability, IOVA's ROE is -0.50%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IOVA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check TLX's competition here
IOVA vs SWTX Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IOVA is priced at $3.55, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IOVA's ROE is -0.50%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, IOVA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check SWTX's competition here
IOVA vs DNTH Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, DNTH has a market cap of 3.3B. Regarding current trading prices, IOVA is priced at $3.55, while DNTH trades at $85.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas DNTH's P/E ratio is -20.35. In terms of profitability, IOVA's ROE is -0.50%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, IOVA is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check DNTH's competition here
IOVA vs VCYT Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, IOVA is priced at $3.55, while VCYT trades at $40.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas VCYT's P/E ratio is 37.74. In terms of profitability, IOVA's ROE is -0.50%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, IOVA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check VCYT's competition here
IOVA vs BEAM Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, IOVA is priced at $3.55, while BEAM trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas BEAM's P/E ratio is -38.85. In terms of profitability, IOVA's ROE is -0.50%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, IOVA is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check BEAM's competition here
IOVA vs ERAS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, IOVA is priced at $3.55, while ERAS trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ERAS's P/E ratio is -23.64. In terms of profitability, IOVA's ROE is -0.50%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, IOVA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ERAS's competition here
IOVA vs DNLI Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, IOVA is priced at $3.55, while DNLI trades at $19.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas DNLI's P/E ratio is -6.64. In terms of profitability, IOVA's ROE is -0.50%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, IOVA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check DNLI's competition here
IOVA vs ALMS Comparison May 2026
IOVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 1.3B. In comparison, ALMS has a market cap of 2.9B. Regarding current trading prices, IOVA is priced at $3.55, while ALMS trades at $23.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -3.26, whereas ALMS's P/E ratio is -8.28. In terms of profitability, IOVA's ROE is -0.50%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, IOVA is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for IOVA.Check ALMS's competition here